Tools & Assets
Explore the most promising technologies from our research laboratories.
Publications
Explore scientific publications straight from our research laboratories.
Key Opinion Leaders
Look no further for Scientific or Medical Expertise
Startups
Find your next strategic partnership or investment.
Clinical Trials
Explore clinical trials being done at Tulane Medicine.
Your BioScience Concierge
Complete Connectivity to Top-Tier Experts, Assets, Tools & Solutions.
1000+
Business Development Interactions per Year
$60M+
Federal Awards in FY2025 for Tulane University School of Medicine
280+
Original research publications in FY22
620+
BioMedical Focused Faculty
Select Focus Areas
Signature Research Strengths Addressing The Worlds Most Compelling Problems.
Examine focus areasSex Differences & Precision Medicine
Tulane holds one of the only Centers of Sex-Based Biology & Medicine in the United States. The center focus is to understand and implement the sex differences that drive certain diseases and conditions, including diabetes, hypertension, osteoporosis, and COVID. These findings will push the research and development of innovative diagnostics and therapeutics specifically tailored to the patient's sex, opening the door for radically improved health outcomes.
Immunology and Microbiology: Vaccine Biology
A rich history of cutting-edge infectious disease research is elevated by vaccine biology, including how pathogens stimulate the immune system to make more effective vaccines. Our adjuvant research program is augmented by a National Biomedical Research Center, home to an array of infectious disease research in HIV/AIDS, emerging viral infections, and vector-borne diseases.
Ultrasensitive and Infectious Disease Diagnostics
A modern twist to infectious disease research applies cutting-edge highly sensitive diagnostics to diseases like COVID-19, Tuberculosis, Lyme Disease, CMV, and more.
T-vant: A Novel Adjuvant for Transformative Vaccines
T-Vant is a potent adjuvant developed by Tulane scientists. This isolated lipid nanoparticle can stimulate not only the B-Cells and CD4+ T-Cells usually associated with vaccine protection, but also stimulates a potent CD8+ T-cell response. This new technology is suitable for use with any microbe or antigen and has been tested in multiple virus and bacterial challenge models.
Publications
Antimicrobial Peptides
Using a unique screening process, Tulane scientists have developed and patented novel antimicrobial peptides with broad spectrum activity. These noncytotoxic peptides are effective against major pathogens with known propensity to developing antimicrobial resistance, including clinical isolates. Bacteria are unable to develop resistance to these peptides under conditions that lead to resistance against traditional small molecule antibiotics.
PDX Model
Triple Negative Breast Cancer is an aggressive subtype of cancer for which there are minimal treatment options. Studying real human tumors and testing drugs against them is critical for developing new treatments for this disease. Tulane has deep expertise in generating and assessing Patient Derived Xenografts (PDX) of this cancer type, along with corresponding organoids and cell lines.
Publications
Infectious Disease Diagnostics
Tulane was founded as a university centered around public health and infectious diseases. Various labs throughout the School of Medicine have continued this tradition by creating novel diagnostics in the global health space, including a tuberculosis point-of-care test and a multiplex Lyme disease test. The university has also pioneered several CRISPR diagnostics ranging from SARS-CoV-2 to Cytomegalovirus to Borrelia and more.
Publications
Tuleviate: A Safer, Non-Addictive Analgesic
Tuleviate is a next-generation analgesic that selectively harnesses the body’s natural pain-relief pathways to deliver potent, long-lasting relief with a dramatically safer profile than traditional treatments. It is effective across a wide range of pain types, including acute, inflammatory, neuropathic, visceral, and postoperative pain.
Pneumoniae Vaccine
Klebsiella pneumoniae is a common bacteria found in the human intestines that cause serious illness if it travels to other parts of the body. Dr. Kolls and Dr. Norton have created an intranasal vaccine for Klebsiella pneumoniae that elicits protection in two ways: antibody and T-cell immunity. All current pneumonia vaccines only elicit antibodies against surface carbohydrates. This is an entirely novel vaccine platform, from the use of the adjuvant to the needle-less route of administration, and it has the potential advantage of providing much broader protection against pneumonia.
Publications
Gene Therapy
Tulane has various tools in the gene therapy space, including a diabetes therapy that induces the preservation of insulin-producing cells and therapy for idiopathic pulmonary fibrosis that aims to reverse scarring in the lungs.
Select Publications
Go In-Depth with Details & Data as We Push the Boundaries of Science & Medicine.
See more publicationsMutational signature analysis predicts bacterial hypermutation and multidrug resistance
Hall, K.M., Williams, L.G., Smith, R.D. et al. , et al.
The study identified a genetic signature in bacteria that, when present, indicates the likelihood of developing antibiotic resistance, said Kalen Hall, PhD, CEO and cofounder of Informuta who spearheaded the research before graduating from Tulane University School of Medicine in 2024.
A rhesus macaque model of congenital cytomegalovirus infection reveals a spectrum of vertical transmission outcomes
Amitinder Kaur, et. al., et al.
Researchers at the Tulane National Biomedical Research Center have published a study that closely follows how cytomegalovirus, or CMV, crosses the placenta during pregnancy and reaches the developing fetus. The findings, published in Communications Biology, may help inform strategies to prevent congenital CMV, the most commonly transmitted mother-to-child infection worldwide and a leading cause of hearing loss and neurodevelopmental problems in infants.
Aetiology of sepsis in adults living with HIV in East Africa: a secondary analysis of an open-label, multicentre, randomised, controlled phase 3 trial
Eva Otoupalova, et. al., et al.
A new study has found that tuberculosis, a chronic bacterial lung disease, is a major and long-overlooked cause of deadly sepsis among people living with HIV. An associated Phase 3 clinical trial called the ATLAS study found that starting tuberculosis (TB) treatment immediately, even before a TB diagnosis is confirmed, could significantly reduce sepsis deaths among HIV patients.
Key Opinion Leaders
Look No Further for Scientific or Medical Influencers. Engage Us for Access to Experts in Other Fields.
Startups
AxoSim
AxoSim's mission is to empower advancements in human neuroscience so that patients in need can get the care they deserve. They deliver human data, faster.
BioAesthetics
BioAesthetics’ mission is to transform lives through advancement in biomaterials, focusing its product pipeline on acellular regenerative grafts for advanced wound and reconstructive care.
Bio Protectant Technologies, Inc.
BPT is a Delaware-domiciled corporation doing business under a foreign entity license in the State of Louisiana. The company is the sole assignee/owner of all majority intellectual property and holds a worldwide exclusive license on auxiliary supporting technology owned by Tulane University. Majority shareholders in BPT are private; the company is also privately capitalized and operated by the beneficial shareholders. For more information, partnering, and investment opportunities, please message us at info@bioprotectant.com
Informuta
Informuta uses computational metagenomics and machine learning to identify the bacterial species causing infection in a patient sample without the need for culturing.
D&P BIO Innovations
Can regenerate a damaged esophagus (organ providing food to the stomach) with its developed medical device implant, as the first of many uses in a platform technology.
Instapath
Instapath is developing cutting-edge fast and easy digital pathology technology so cancer diagnosis can be made in minutes instead of days.
MDR Therapeutics
MDR Therapeutics has developed a platform-based vaccine technology that elicits first in class bacterial specific mucosal immune responses including both T cell and B cell responses.
NanoPin
NanoPin's mission is to advance infectious disease diagnosis and improve patient care using novel diagnostic platforms that produces rapid and accurate results from patient samples.
Obatala
Obatala offers research enabling products and brain power to scientists in industry and aacademia, with the goal of advancing tissue engineering and regenerative medicine.
Zalgen
Zalgen Labs was founded on the concept of developing solutions to emerging viral threats in neglected regions of the world.
IntelliGenome
IntelliGenome pioneers diagnostic technology to tackle serious health challenges, particularly in infectious diseases. They have developed the first CRISPR-based molecular diagnostic detection assay for low-abundance nucleic acids in small blood samples, and a high-throughput tuberculosis test that delivers reliable results in hours. Their adaptable platform aims to transform disease diagnosis, especially in low- and medium-income countries.
Our team is always available.
Elaine Hamm, PhD
Executive in Residence
Elaine Hamm, PhD, is the CEO of the pharmaceutical accelerator, Ascend BioVentures where she manages early stage life science startups and evaluates the commercial potential of life science technologies, and as the Executive in Residence for the Tulane SoM she shares her expertise to elevate the connectivity between the Tulane and our corporate and investor community. Prior to joining Tulane and Ascend BioVentures, Dr. Hamm was the COO of Accele BioPharma and served as management for a portfolio of early stage pharmaceutical companies ranging from diabetes to hearing loss to infectious disease. Dr. Hamm has 13 years of professional leadership experience in the commercialization of early stage pharmaceutical therapeutics and diagnostics with experience in technology transfer, market analysis, and commercialization of preclinical and clinical stage products. She has designed and served as the Director for several, statewide start-up accelerator programs. Dr. Hamm also has experience in equity and nonequity funding of early stage companies and has been directly involved in closing almost $30M in equity investment deals, with a focus in the pharmaceutical industry and recently closed a $100M+ deal with a large pharmaceutical partner. In addition to her commercialization experience, Dr. Hamm has also worked a Senior Protein chemist in discovery and pre-clinical development of new chemical entities. Dr. Hamm received her PhD in Microbiology from the University of Oklahoma and holds several licensed US and International patents.
Carolyn Scofield, MPS
Director, Marketing & Communications
Carolyn Scofield, MPS, (’21, Tulane School of Professional Advancement) joined Tulane University in 2015 after more than 14 years as a television news reporter. Her initial role in public relations often brought her to the School of Medicine to cover stories about groundbreaking research and connect media with leading experts. As the Assistant Director for Marketing and Communications at the School of Medicine, Carolyn is continuing that work overseeing the team that reports on research and expertise and ensures that departments, programs and people share their discoveries and solutions with the world. She has a special talent for bringing science to life through a variety of media and ensuing that everyone (from business development executives to the general public) can understand what the latest groundbreaking research at Tulane could mean for them. Carolyn has a master’s degree in emergency management, a field that studies everything from natural disasters to reputational crises. She has an extensive background in television and radio broadcasting, journalism and social media.
Lindsey Jardine
Executive Expert in Clinical & Regulatory Affairs
Lindsey Jardine, with exceptional experience in strategic clinical, regulatory and operational affairs, advises the SoM as the Executive Expert in Clinical & Regulatory Affairs.
Nicholas Pashos, PhD
Entrepreneur in Residence
Nicholas Pashos, PhD, Founder and CEO at BioAesthetics is the Entrepreneur in Residence, Advising Faculty, Staff and Students on how to best achieve their Entrepreneurial goals.